Alternative ways to correct poor glucose metabolism in patient with diabetes mellitus

Leonid Sevastyanov 1 * , Yermek Turgunov 1, Jean-Pierre Faure 2, Dmitriy Shestakov 1
More Detail
1 Karaganda Medical University, Karaganda, Kazakhstan
2 University of Poitiers, Poitiers, France
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 5, pp. 30-34.
OPEN ACCESS 753 Views 535 Downloads
Download Full Text (PDF)


There is an annual increase in the incidence of diabetes recorded worldwide. The existing measures of prevention and multimodal treatment of the disease have not yet brought the desired results. A promising field is bariatric (metabolic) operations used in obese patients, which also improve glucose metabolism in the case of concomitant diabetes mellitus of both types 1 and 2. At the same time, there is a certain contradiction and understatement regarding the mechanisms that lead to remission of diabetes mellitus, regardless of weight loss. One of the anatomical effects of bariatric procedures is the accelerated release of nutrients into the distal segment of the small intestine, which leads to stimulation of enteroendocrine cells and increased secretion of incretins (GLP-1, PYY, etc.). The experiment investigates these mechanisms by the operation of ileal transposition. Further study of the ileal transposition effects using different models of type 1 and type 2 diabetes, accompanied both with and without obesity, may contribute to a more detailed understanding of the triggering and supporting mechanisms of increasing glucose tolerance in the struggle against this disease.


Sevastyanov L, Turgunov Y, Faure JP, Shestakov D. Alternative ways to correct poor glucose metabolism in patient with diabetes mellitus. J CLIN MED KAZ. 2021;18(5):30-4.


  • Global report on diabetes. WHO, 2016. [Electronic resource]. – Access mode:
  • Foster D, Sanchez-Collins S, Cheskin LJ. Erratum: multidisciplinary team-based obesity treatment in patients with diabetes: current practices and the state of the science. Diabetes Spectr. 2017; 30: 244–249.
  • Estimated global healthcare expenditure to treat diabetes in 2019 and 2045, 2019. [Electronic resource]. – Access mode:
  • Chamberlain JJ. et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann. Intern. med. – 2016; 19;164(8):542-52
  • Pugliese G, Vitale M, Resi V, Orsi E. Is diabetes mellitus a risk factor for CoronaVIrus Disease 19 (COVID-19)? Acta Diabetol. 2020; 57, 1275–1285.
  • Affinati AH, Esfandiari NH, Oral EA, Kraftson A. T. Bariatric Surgery in the Treatment of Type 2 Diabetes. Curr. Diabetes Rep. 2019; 19(12): 156.
  • Pappachan JM, Viswanath AK. Medical management of diabesity: do we have realistic targets? Curr. Diabetes Rep. 2017; 17(1):4.
  • Kornyushin OV, Galagudza MM., Neimark AE, Babenko AYu, Grineva E.N. Ileal transposition in surgical treatment for type 2 diabetes mellitus. Diabetes Mellitus. 2015; 18:58-64. Russian.
  • Ersoz F, Duzkoylu Y, Deniz MM, Boz M. Laparoscopic Roux-en-Y gastric bypass with ileal transposition - an alternative surgical treatment for type 2 diabetes mellitus and gastroesophageal reflux. Wideochir Inne Tech Maloinwazyjne. 2015; 10:481–5.
  • Ahuja A, Tantia O, Chaudhuri T, Shashi K, Shivakumar S, Kajari M et al. Predicting remission of diabetes post metabolic surgery: a comparison of ABCD, diarem, and DRS scores. Obes Surg. 2018; 28:2025–31.
  • Park CH, Nam SJ, Choi HS, Kim KO, Kim DH et al. Korean Research Group for Endoscopic Management of Metabolic Disorder and Obesity. Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: a Systematic Review and Network Meta-Analysis. Obes Surg. 2019; 29(7): 2180-2190.
  • Praveen Raj P, Bhattacharya S, Saravana Kumar S, Sabnis SC, Parthasarathi R, Swamy PDK, et al. Do Bariatric Surgery-Related Type 2 Diabetes Remission Predictors Add Clinical Value? A Study on Asian Indian Obese Diabetics. Obes Surg. 2017; 27: 2113-9.
  • Lee WJ, Chong K, Chen SC, James Z, Kong-Han S, Lee YCh, et al. Preoperative Prediction of Type 2 Diabetes Remission After Gastric Bypass Surgery: a Comparison of DiaRem Scores and ABCD Scores. Obes Surg. 2016; 26: 2418-24.
  • Min T, Barry JD, Stephens JW. Predicting the Resolution of Type 2 Diabetes after Bariatric Surgical Procedures: A Concise Review. Diabetes Metab.. 2015; 6: 1-5.
  • Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31.
  • Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36. discussion 636–7.
  • Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420–8.
  • Lakdawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30–35 kg/m2 ) Indian patients with type 2 diabetes mellitus. Surg Obes Relat Dis. 2013;9:370–8.
  • Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis. 2013;9:7–14.
  • Sultan S, Gupta D, Parikh M, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2010;6:373–376.
  • Hussain A. The effect of metabolic surgery on type 1 diabetes: meta-analysis. Arch endocrin metab. 2018; 62: 172-8.
  • Mottalib A, Kasetty M, Mar JY, Elseaidy T, Ashrafzadeh S, Hamdy O. Weight Management in Patients with Type 1 Diabetes and Obesity. Curr. Diabetes Rep. 2017; 17:92.
  • Chow A, Switzer NJ, Dang J, Xinzhe S, de Gara Ch, Birch DW, et al. A Systematic Review and Meta-analysis of outcomes for Type 1 diabetes after bariatric surgery. J. Obes. 2016; 6170719.
  • Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM. Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Obes surg. 2019; 29:964-974.
  • Quevedo M, Palermo M, Serra E, Ackermann MA. Metabolic surgery: gastric bypass for the treatment of type 2 diabetes mellitus. Transl. Gastroenterol. Hepatol. 2017; 2(6):p. 58.
  • Wang JL., Xu XH, Zhang XJ, Li WH. The role of obestatin in roux-en-Y gastric bypass-induced remission of type 2 diabetes mellitus. Diabetes Metab Res Rev. (2016) 32:470–7.
  • Argyropoulos G. Bariatric Surgery: Prevalence, predictors, and mechanisms of diabetes remission. Curr. Diab. Rep. 2015; 15:15.
  • Esposito K, Maiorino MI, Petrizzo M, Bellastella G, Giugliano D. Remission of type 2 diabetes: Is bariatric surgery ready for prime time? Endocrine. 2015; 48:417–421.
  • Hutch CR., Sandoval D. The Role of GLP-1 in the Metabolic Success of Bariatric Surgery. Endocrinology. 2017; 158:4139–4151.
  • Buchwald H, Buchwald JN. Metabolic (bariatric and nonbariatric) surgery for type 2 diabetes: a personal perspective review. Diabetes Care. 2019; 42(2):331–340.
  • Ahn CH, Chae S, Oh TJ, Hwang D, Cho YM. Dynamic Adaptive Changes of the Ileum Transposed to the Proximal Small Intestine in Rats. Obes Surg. 2019; 29:2399–2408.
  • Boza C, Muñoz R, Yung E, Milone L, Gagner M. Sleeve Gastrectomy with Ileal Transposition (SGIT) Induces a Significant Weight Loss and Diabetes Improvement Without Exclusion of the Proximal Intestine. J. Gastrointest. Surg. 2011. - 15(6), 928–934.
  • Oh TJ, Ahn CH, Cho YM. Contribution of the distal small intestine to metabolic improvement after bariatric/metabolic surgery: Lessons from ileal transposition surgery. J Diabetes Investig. 2016; 7(Suppl 1):94–101.
  • Yan K, Chen W, Zhu H, Lin G, Pan H, Li N, et al. Ileal Transposition Surgery Decreases Fat Mass and Improves Glucose Metabolism in Diabetic GK Rats: Possible Involvement of FGF21. Front Physiol. 2018; 9:191.
  • Gao Z, Wang B, Gong X, Yao C, Ren D, Shao L, et al. Effect of gastric bypass combined with ileal transportation on type 2 diabetes mellitus. Exp Ther Med. 2018; 15:4571–7.
  • Celik A, Asci M, Celik BO, Ugale S. The impact of laparoscopic diverted sleeve gastrectomy with ileal transposition (DSIT) on short-term diabetic medication costs. Springerplus. 2015;4:417.
  • Celik A, Ugale S, Ofluoglu H, Vural E, Cagiltay E, Cat H, et al. Metabolic Outcomes of Laparoscopic Diverted Sleeve Gastrectomy with Ileal Transposition (DSIT) in Obese Type 2 Diabetic Patients. Obes Surg. 2015; 25:2018–22.
  • Kornyushin OV, Bakhtyukov AA, Zorina I., Toropova YaG, Derkach KV, Berko OM, et al. The effect of different types of bariatric surgery on the metabolic and hormonal parameters in rats with decompensed form of type 2 diabetes mellitus. Adv Gerontol. 2019; 32(1-2):85-92. Russian.
  • Mufide NA, Erdem K, Ali A. Bariatric/Metabolic Surgery in Type 1 and Type 2 Diabetes Mellitus // Eurasian J Med. 2019 Feb; 51(1): 85–89.
  • Moreno-Fernandez J, Chico A. Bariatric surgery results in patients with type 1 diabetes mellitus on continuous subcutaneous insulin infusion therapy. Endocrinol Nutr. 2016; 63: 571-2.
  • Prada-Oliveira JA, Camacho-Ramirez A, Salas-Alvarez J, Campos-Martinez FJ, Lechuga-Sancho AM, Almorza-Gomar D. et al. GLP-1 mediated improvement of the glucose tolerance in the T2DM GK rat model after massive jejunal resection. Ann Anat. 2019; 223:1-7.
  • Guida C, Stephen S, Guitton R, Ramracheya RD. The Role of PYY in Pancreatic Islet Physiology and Surgical Control of Diabetes. Trends Endocrinol Metab. 2017; (8):626-636.
  • Hung C, Napoli E, Ross-Inta C, Graham J, Flores-Torres AL, Stanhope KL. et al. Ileal interposition surgery targets the hepatic TGF-β pathway, influencing gluconeogenesis and mitochondrial bioenergetics in the UCD-T2DM rat model of diabetes. FASEB J. 2019; 33(10):11270-11283.
  • Amouyal C, Andreelli F. Increasing GLP-1 circulating levels by bariatric surgery or by GLP-1 receptor agonists therapy: why are the clinical consequences so different? J Diabetes Res. 2016;2016: 5908656.
  • Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: A new perspective for an old disease. Ann. Surg. 2004;239:1–11.
  • Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann. Surg. 2006; 244:741–749.
  • Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and Type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248-56.
  • Hironaka J, Kitahama S, Sato H, Inoue M, Takahashi T, Tamori Y. Sleeve Gastrectomy Induced Remission of Slowly Progressive Type 1 Diabetes in a Morbidly Obese Japanese Patient. Intern Med. 2019; 58(5): 675–678.
  • Robert M, Belanger P, Hould FS, Marceau S, Tchernof A, Biertho L. Should metabolic surgery be offered in morbidly obese patients with type i diabetes? Surg Obes Relat Dis. 2015;11(4):798–805.
  • Mikhaylichenko VYu, Stolyarov SS, Starykh AA. Pathophysiological aspects of the development of alloxan diabetes mellitus in rats in experiment. Modern Problems of Science and Education. 2015; (5): 23.
  • Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina, 2017;53(6):365–374.
  • Ahn CH, Choi EH, Oh TJ, Cho YM. Ileal Transposition Increases Pancreatic β-Cell Mass and Decreases β-Cell Senescence in Diet-Induced Obese Rats. Obes surg 30. 2020; 1849–1858.